Adeno-associated viral vectors (AAV) have emerged as key players in this growth trajectory, projected to capture a ...

The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis.

A research team has established a virus-induced gene silencing (VIGS) system in taro, enabling researchers to rapidly verify ...

Purespring’s gene therapy, PS-002, uses a viral vector to target kidney cells—known as podocytes—to treat IgA nephropathy, a ...

Its lead gene therapy candidate has the potential to be faster, less expensive, and more widely available than current CAR T ...

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.

RCCS San Raffaele Scientific Institute in Milan researchers have discovered that hematopoietic stem cells (HSCs) adapt their lineage commitment during gene therapy based on the underlying genetic ...

In this GEN webinar, Andrea O'Hara, PhD, a multiomics expert at GENEWIZ from Azenta Life Sciences, will discuss how to use ...

Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) for viral vectors, ...